Biotechnology
Technology
Health

DBV Technologies

$9.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.33 (3.60%) As of 10:26 AM EDT today
+$0.33 (3.60%) Today

Why Robinhood?

You can watch DBVT and buy or sell other stocks, options, ETFs, and crypto commission-free!

About DBVT

DBV Technologies S.A. American Depositary Shares, also called DBV Technologies, is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. Read More It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Employees
315
Headquarters
Montrouge, Ile-de-France
Founded
2002
Market Cap
661.77M
Price-Earnings Ratio
Dividend Yield
Average Volume
166.77K
High Today
$9.55
Low Today
$9.34
Open Price
$9.37
Volume
67.35K
52 Week High
$25.77
52 Week Low
$3.60

Collections

Biotechnology
Technology
Health
Medical
Biopharmaceutical
Research And Development
Pharmaceutical
2014 IPO

DBVT News

BenzingaAug 8

DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies

7

Popular Stocks

More DBVT News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.